- Home
- VNO vs PTGX Comparison
VNO vs PTGX Comparison
Compare VNO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNO | PTGX |
|---|---|---|
| Founded | 1946 | 2006 |
| Country | United States | United States |
| Employees | 3145 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | VNO | PTGX |
|---|---|---|
| Price | $40.34 | $128.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $33.00 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 1.7M | 720.9K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $874.25 |
| Revenue Next Year | $5.42 | N/A |
| P/E Ratio | ★ $7.08 | $2,634.10 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.57 | $50.49 |
| 52 Week High | $43.37 | $131.87 |
Technical Indicators
Market Signals| Indicator | VNO | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 74.44 | 79.05 |
| Support Level | $39.73 | $94.48 |
| Resistance Level | $41.42 | N/A |
| Average True Range (ATR) | 1.00 | 4.70 |
| MACD | 0.04 | 1.46 |
| Stochastic Oscillator | 99.53 | 99.29 |
Price Performance
Historical ComparisonAbout VNO Vornado Realty Trust
Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.